什么是PGC-1alpha,在亨廷顿病的新治疗目标?
1Department of Neurology, Cornell Medical Center, New York, NY 10021, USA.
Cell
|November 4, 2006
概括
在亨廷顿病 (HD) 中,对能量代谢至关重要的协活性剂PGC-1alpha的下调. 这一发现将受损的线粒体功能与HD患者和模型中的神经退行联系起来.
科学领域:
- 线粒体生物学 线粒体生物学
- 神经退行性疾病的神经退行性疾病
- 疾病的分子机制.
背景情况:
- PGC-1alpha 是线粒体生物发生和细胞呼吸的主要调节者.
- 线粒体功能障碍越来越多地与神经退行性疾病的发病有关.
- 亨廷顿病 (HD) 是一种致命的神经退行性疾病,其机制尚不清楚.
研究的目的:
- 调查PGC-1alpha在亨廷顿病 (HD) 中的作用.
- 为了确定PGC-1α表达是否在HD患者和动物模型中发生变化.
- 探索PGC-1α,能量代谢和HD中神经退行之间的联系.
主要方法:
- 在患者衍生样本和HD动物模型中分析PGC-1α表达水平.
- 评估线粒体生物发生和呼吸标志物.
- PGC-1α水平与疾病严重程度和进展的相关性.
主要成果:
- 三项独立研究一致显示,在HD中PGC-1α表达减少.
- 在人类HD患者和各种HD动物模型中观察到PGC-1alpha的下调.
- 线粒体功能和能量代谢受损与HD中的PGC-1α降低有关.
结论:
- PGC-1α在亨廷顿病的发病过程中起着重要作用.
- 降低PGC-1α有助于HD中观察到的能量代谢受损.
- 准PGC-1alpha可能为亨廷顿病提供治疗策略.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
77
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
G Protein-coupled Receptors
19.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.6K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
GPCRs Regulate Adenylyl Cylase Activity
8.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K
GPCR Desensitization
8.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.7K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K


